Needham analyst Joseph Stringer maintained a Hold rating on Theravance Biopharma (TBPH – Research Report) today. The company's shares closed last Wednesday at $8.63. According to TipRanks.com, Stringer 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -12.2% and a 34.6% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Apellis Pharmaceuticals, and Lexicon Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Theravance Biopharma with a $11.17 average price target.
https://www.tipranks.com/news/blurbs/theravance-biopharma-tbph-receives-a-hold-from-needham-2?utm_source=advfn.com&utm_medium=referral
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Theravance Biopharma Charts.
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Theravance Biopharma Charts.